Sec Form 4 Filing - Legorreta Pablo G. @ Royalty Pharma plc - 2023-06-12

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Legorreta Pablo G. 2. Issuer Name and Ticker or Trading Symbol Royalty Pharma plc [ RPRX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner X __ Officer (give title below) _____ Other (specify below) CEO, Chairman of the Board (Last) (First) (Middle) C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET 3. Date of Earliest Transaction (MM/DD/YY) 06/12/2023 (Street) NEW YORK, NY10022 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Class A ordinary shares 06/12/2023 P( 1 ) 45,000 A $ 32.9988 ( 2 ) 425,000 I By Legorreta 2023 SR Trust Class A ordinary shares 06/13/2023 P( 1 ) 45,000 A $ 32.7756 ( 3 ) 470,000 I By Legorreta 2023 SR Trust Class A ordinary shares 63,795 D Class A ordinary shares 460,139 I By Legorreta Investments LLC Class A ordinary shares 1,284,590 I By GST-Exempt Legorreta 2012 Family Trust Class A ordinary shares 41,306 I By GST-Exempt Legorreta 2020 Family Trust Class A ordinary shares 10,000 I By Child Class A ordinary shares 10,000 I By Child Class A ordinary shares 123,310 I By IRRA Class A ordinary shares 118,500 I By SEP/IRA Class A ordinary shares 1,040,410 I By Legorreta Children 2002 Trust Class A ordinary shares 6,930 I By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Legorreta Pablo G. C/O ROYALTY PHARMA PLC 110 E. 59TH STREET NEW YORK, NY10022 X X CEO, Chairman of the Board Signatures /s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta 06/13/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents shares acquired by the reporting person in open market transactions as part of the reporting person's previously disclosed intention to purchase up to $50 million of the issuer's Class A ordinary shares, as announced in the issuer's press release on March 27, 2023 regarding the issuer's $1.0 billion share repurchase program. ( 2 )The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $32.97 to $33.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range. ( 3 )The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $32.66 to $32.80. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.